Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $3.92 Average Target Price from Analysts

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) have received a consensus rating of “Reduce” from the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $3.9167.

A number of brokerages recently commented on PLRX. Wall Street Zen upgraded Pliant Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Thursday, January 22nd.

Insider Buying and Selling

In other Pliant Therapeutics news, CEO Bernard Coulie sold 89,375 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $1.28, for a total transaction of $114,400.00. Following the completion of the transaction, the chief executive officer directly owned 505,601 shares in the company, valued at $647,169.28. The trade was a 15.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Pliant Therapeutics

Institutional investors have recently modified their holdings of the business. Monaco Asset Management SAM acquired a new position in Pliant Therapeutics during the 2nd quarter worth approximately $815,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Pliant Therapeutics during the second quarter worth $39,000. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Pliant Therapeutics by 119.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 35,540 shares of the company’s stock valued at $41,000 after acquiring an additional 19,320 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Pliant Therapeutics by 136.6% in the 2nd quarter. Jane Street Group LLC now owns 323,412 shares of the company’s stock valued at $375,000 after acquiring an additional 186,696 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Pliant Therapeutics during the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 97.30% of the company’s stock.

Pliant Therapeutics Price Performance

Pliant Therapeutics stock opened at $1.30 on Tuesday. The firm has a market cap of $79.89 million, a PE ratio of -0.45 and a beta of 1.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.94 and a quick ratio of 13.93. The stock’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.44. Pliant Therapeutics has a one year low of $1.09 and a one year high of $3.46.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).